- Conditions
- Norovirus Acute Gastroenteritis
- Interventions
- mRNA-1403, mRNA-1405, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,407 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–46
of 46
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Meningococcal Meningitis
- Interventions
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 37 Months to 63 Months
- Enrollment
- 433 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Downey, California • Oakland, California + 15 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- MVA-BN-RSV, Placebo
- Biological · Other
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 12
- States / cities
- Redding, California • San Diego, California • The Villages, Florida + 9 more
- Conditions
- Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma, Lung Neoplasms
- Interventions
- Drug: Hyperacute Lung Cancer Cell Vaccine
- Biological
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, mRNA-1273.231
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,161 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 23
- States / cities
- Sacramento, California • Hollywood, Florida • Jacksonville, Florida + 18 more
- Conditions
- Neuroblastoma
- Interventions
- β-glucan, GM-CSF, OPT-821
- Dietary Supplement · Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 286 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
- Interventions
- PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
- Biological · Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more
- Conditions
- SARS-CoV Infection, Covid19
- Interventions
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
- Biological · Other
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 33,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more
- Conditions
- Dengue
- Interventions
- TV003 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Burlington, Vermont
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
- Interventions
- galinpepimut-S, pembrolizumab, Montanide, GM-CSF
- Biological · Other
- Lead sponsor
- Sellas Life Sciences Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 12
- States / cities
- Santa Rosa, California • Whittier, California • Miami, Florida + 9 more
- Conditions
- Breast Cancer Metastatic Breast Cancer, HER2-negative Breast Cancer
- Interventions
- Elacestrant, DC1 native/mutated ESR1
- Drug · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Prostate Cancer
- Interventions
- Proscavax
- Biological
- Lead sponsor
- OncBioMune Pharmaceuticals
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreatic Cancer
- Interventions
- GVAX pancreatic cancer vaccine
- Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Herpes Zoster
- Interventions
- HZ/su, Flu D-QIV, mRNA-1273
- Biological · Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,013 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 46
- States / cities
- Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
- Conditions
- Breast Cancer
- Interventions
- Herceptin, NeuVax vaccine, GM-CSF
- Drug
- Lead sponsor
- George E. Peoples
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 29
- States / cities
- Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more
- Conditions
- COVID -19
- Interventions
- RVX-sCPD9
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- New York, New York • Durham, North Carolina • Cincinnati, Ohio + 1 more
- Conditions
- Malignant Glioma
- Interventions
- Dendritic vaccine pulsed with multiple peptides, The first booster vaccine phase:, The second booster vaccine phase:
- Biological
- Lead sponsor
- Frank Lieberman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
- Biological
- Lead sponsor
- Seema Bhat
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Tick-Borne Encephalitis
- Interventions
- LGT(TP21)/DEN4, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
- Interventions
- Ad26.COV2.S, Placebo
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31,835 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 63
- States / cities
- Vestavia Hills, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
- Interventions
- ELI-002 2P
- Drug
- Lead sponsor
- Elicio Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- Breast Cancer
- Interventions
- Low dose FRα vaccine, Cyclophosphamide, High dose FRα vaccine
- Biological · Drug
- Lead sponsor
- Marker Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 11
- States / cities
- Tampa, Florida • Westwood, Kansas • Baltimore, Maryland + 7 more